<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.01.02.20248998</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Infectious Diseases (except HIV/AIDS)</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Trombetta</surname><given-names>Bianca A.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kandigian</surname><given-names>Savannah E.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kitchen</surname><given-names>Robert R.</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Grauwet</surname><given-names>Korneel</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kivis&#x00E4;kk Webb</surname><given-names>Pia</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Miller</surname><given-names>Glenn A.</given-names></name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jennings</surname><given-names>Charles G.</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jain</surname><given-names>Sejal</given-names></name>
<xref ref-type="aff" rid="a6">6</xref>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Miller</surname><given-names>Samara</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a8">8</xref>
<xref ref-type="aff" rid="a9">9</xref>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kuo</surname><given-names>Yikai</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sweeney</surname><given-names>Thadryan</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gilboa</surname><given-names>Tal</given-names></name>
<xref ref-type="aff" rid="a11">11</xref>
<xref ref-type="aff" rid="a12">12</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Norman</surname><given-names>Maia</given-names></name>
<xref ref-type="aff" rid="a11">11</xref>
<xref ref-type="aff" rid="a12">12</xref>
<xref ref-type="aff" rid="a13">13</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Simmons</surname><given-names>Daimon P.</given-names></name>
<xref ref-type="aff" rid="a14">14</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ramirez</surname><given-names>Christopher E.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bedard</surname><given-names>Melissa</given-names></name>
<xref ref-type="aff" rid="a14">14</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fink</surname><given-names>Catherine</given-names></name>
<xref ref-type="aff" rid="a15">15</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ko</surname><given-names>Jina</given-names></name>
<xref ref-type="aff" rid="a11">11</xref>
<xref ref-type="aff" rid="a16">16</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>De Le&#x00F3;n Peralta</surname><given-names>Esmarline J.</given-names></name>
<xref ref-type="aff" rid="a17">17</xref>
<xref ref-type="aff" rid="a18">18</xref>
<xref ref-type="aff" rid="a19">19</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Watts</surname><given-names>Gerald</given-names></name>
<xref ref-type="aff" rid="a14">14</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gomez-Rivas</surname><given-names>Emma</given-names></name>
<xref ref-type="aff" rid="a14">14</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Davis</surname><given-names>Vannessa</given-names></name>
<xref ref-type="aff" rid="a12">12</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Barilla</surname><given-names>Rocky</given-names></name>
<xref ref-type="aff" rid="a20">20</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Jianing</given-names></name>
<xref ref-type="aff" rid="a8">8</xref>
<xref ref-type="aff" rid="a21">21</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cunin</surname><given-names>Pierre</given-names></name>
<xref ref-type="aff" rid="a14">14</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bates</surname><given-names>Samuel</given-names></name>
<xref ref-type="aff" rid="a22">22</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Morrison-Smith</surname><given-names>Chevaun</given-names></name>
<xref ref-type="aff" rid="a12">12</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nicholson</surname><given-names>Benjamin</given-names></name>
<xref ref-type="aff" rid="a23">23</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wong</surname><given-names>Edmond</given-names></name>
<xref ref-type="aff" rid="a23">23</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>El-Mufti</surname><given-names>Leena</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kann</surname><given-names>Michael</given-names></name>
<xref ref-type="aff" rid="a23">23</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bolling</surname><given-names>Anna</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fortin</surname><given-names>Brooke</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ventresca</surname><given-names>Hayden</given-names></name>
<xref ref-type="aff" rid="a21">21</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhou</surname><given-names>Wen</given-names></name>
<xref ref-type="aff" rid="a24">24</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pardo</surname><given-names>Santiago</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kwock</surname><given-names>Megan</given-names></name>
<xref ref-type="aff" rid="a25">25</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hazra</surname><given-names>Aditi</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a26">26</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cheng</surname><given-names>Leo</given-names></name>
<xref ref-type="aff" rid="a27">27</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ahmad</surname><given-names>Q. Rushdy</given-names></name>
<xref ref-type="aff" rid="a11">11</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Toombs</surname><given-names>James A.</given-names></name>
<xref ref-type="aff" rid="a11">11</xref>
<xref ref-type="aff" rid="a28">28</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Larson</surname><given-names>Rebecca</given-names></name>
<xref ref-type="aff" rid="a29">29</xref>
<xref ref-type="aff" rid="a30">30</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pleskow</surname><given-names>Haley</given-names></name>
<xref ref-type="aff" rid="a23">23</xref>
<xref ref-type="aff" rid="a31">31</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Luo</surname><given-names>Nell Meosky</given-names></name>
<xref ref-type="aff" rid="a31">31</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Samaha</surname><given-names>Christina</given-names></name>
<xref ref-type="aff" rid="a31">31</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pandya</surname><given-names>Unnati M.</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a33">33</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>De Silva</surname><given-names>Pushpamali</given-names></name>
<xref ref-type="aff" rid="a18">18</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhou</surname><given-names>Sally</given-names></name>
<xref ref-type="aff" rid="a34">34</xref>
<xref ref-type="aff" rid="a35">35</xref>
<xref ref-type="aff" rid="a36">36</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ganhadeiro</surname><given-names>Zakary</given-names></name>
<xref ref-type="aff" rid="a34">34</xref>
<xref ref-type="aff" rid="a35">35</xref>
<xref ref-type="aff" rid="a36">36</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yohannes</surname><given-names>Sara</given-names></name>
<xref ref-type="aff" rid="a28">28</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gay</surname><given-names>Rakiesha</given-names></name>
<xref ref-type="aff" rid="a28">28</xref>
<xref ref-type="aff" rid="a35">35</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Slavik</surname><given-names>Jacqueline</given-names></name>
<xref ref-type="aff" rid="a28">28</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mukerji</surname><given-names>Shibani S.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jarolim</surname><given-names>Petr</given-names></name>
<xref ref-type="aff" rid="a7">7</xref>
<xref ref-type="aff" rid="a12">12</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5524-7348</contrib-id>
<name><surname>Walt</surname><given-names>David R.</given-names></name>
<xref ref-type="aff" rid="a11">11</xref>
<xref ref-type="aff" rid="a12">12</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Carlyle</surname><given-names>Becky C.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ritterhouse</surname><given-names>Lauren L.</given-names></name>
<xref ref-type="aff" rid="a17">17</xref>
<xref ref-type="author-notes" rid="n2">&#x002A;&#x002A;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5154-576X</contrib-id>
<name><surname>Suliman</surname><given-names>Sara</given-names></name>
<xref ref-type="aff" rid="a14">14</xref>
<xref ref-type="author-notes" rid="n2">&#x002A;&#x002A;</xref>
<xref ref-type="corresp" rid="cor1">&#x0023;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Department of Neurology, Massachusetts General Hospital, Harvard Medical School</institution>, Charlestown, Boston, MA</aff>
<aff id="a2"><label>2</label><institution>Department of Medicine, Harvard Medical School</institution>, Boston, MA</aff>
<aff id="a3"><label>3</label><institution>Mass General Brigham Innovation</institution>, Boston, MA</aff>
<aff id="a4"><label>4</label><institution>Cardiology Division, Massachusetts General Hospital</institution>, Charlestown, MA</aff>
<aff id="a5"><label>5</label><institution>Department of Neurosurgery, Brigham and Women&#x2019;s Hospital, Harvard Medical School</institution>, Boston, MA</aff>
<aff id="a6"><label>6</label><institution>Department of Medical Oncology and Center for Cancer-Genome Discovery, Dana-Farber Cancer Institute</institution>, Boston, MA</aff>
<aff id="a7"><label>7</label><institution>Department of Pathology, Harvard Medical School</institution>, Boston, MA</aff>
<aff id="a8"><label>8</label><institution>Center for Regenerative Medicine, Massachusetts General Hospital</institution>, Boston, MA</aff>
<aff id="a9"><label>9</label><institution>Harvard Stem Cell Institute</institution>, Cambridge, MA</aff>
<aff id="a10"><label>10</label><institution>Department of Psychiatry, Massachusetts General Hospital</institution>, Boston, MA</aff>
<aff id="a11"><label>11</label><institution>Wyss Institute for Biologically Inspired Engineering, Harvard University</institution>, Boston, MA</aff>
<aff id="a12"><label>12</label><institution>Department of Pathology, Brigham and Women&#x2019;s Hospital, Harvard Medical School</institution>, Boston, MA</aff>
<aff id="a13"><label>13</label><institution>Sackler School of Biomedical Sciences, Tufts University School of Medicine</institution>, Boston, MA</aff>
<aff id="a14"><label>14</label><institution>Division of Rheumatology, Inflammation and Immunity, Brigham and Women&#x2019;s Hospital</institution>, Boston, MA</aff>
<aff id="a15"><label>15</label><institution>Medical Diagnostic Technology Evaluation</institution>, LLC, Carlisle, MA</aff>
<aff id="a16"><label>16</label><institution>Center for Systems Biology, Massachusetts General Hospital</institution>, Boston, MA</aff>
<aff id="a17"><label>17</label><institution>Department of Pathology, Massachusetts General Hospital</institution>, Boston, MA</aff>
<aff id="a18"><label>18</label><institution>Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School</institution>, Boston, MA</aff>
<aff id="a19"><label>19</label><institution>Department of Dermatology, Massachusetts General Hospital</institution>, Boston, MA</aff>
<aff id="a20"><label>20</label><institution>Evergrande Center for Immunologic Diseases, Brigham and Women&#x2019;s Hospital</institution>, Boston, MA</aff>
<aff id="a21"><label>21</label><institution>Mass General Hospital Institute of Health Professions</institution>, Charlestown, MA</aff>
<aff id="a22"><label>22</label><institution>Functional Genomics Laboratory, Channing Division of Network Medicine, Brigham and Women&#x2019;s Hospital</institution>, Boston, MA</aff>
<aff id="a23"><label>23</label><institution>Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School</institution>, Charlestown, MA</aff>
<aff id="a24"><label>24</label><institution>Division of Nephrology and Endocrine Unit Department of Medicine, Massachusetts General Hospital</institution>, Boston, MA</aff>
<aff id="a25"><label>25</label><institution>Cancer Center Protocol Office, Massachusetts General Hospital</institution>, Boston, MA</aff>
<aff id="a26"><label>26</label><institution>Division of Preventative Medicine, Brigham and Women&#x2019;s Hospital, Harvard Medical School</institution>, Boston, MA</aff>
<aff id="a27"><label>27</label><institution>Radiology and pathology, Massachusetts General Hospital, Harvard Medical School</institution>, Boston, MA</aff>
<aff id="a28"><label>28</label><institution>Brigham Research Institute, Brigham and Women&#x2019;s Hospital</institution>, Boston, MA</aff>
<aff id="a29"><label>29</label><institution>Immunology Program, Harvard Medical Schoo</institution>l, Boston, MA</aff>
<aff id="a30"><label>30</label><institution>Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital</institution>, Boston, Massachusetts, <country>USA</country></aff>
<aff id="a31"><label>31</label><institution>Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School</institution>, Boston, MA</aff>
<aff id="a32"><label>32</label><institution>Folia Health, Inc.</institution>, Cambridge, MA</aff>
<aff id="a33"><label>33</label><institution>Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital</institution>, Boston, MA</aff>
<aff id="a34"><label>34</label><institution>Department of Biology, Northeastern University</institution>, Boston, MA</aff>
<aff id="a35"><label>35</label><institution>College of Science, Northeastern University</institution>, Boston, MA</aff>
<aff id="a36"><label>36</label><institution>Mass General Brigham COVID Center for Innovation, Diagnostics Accelerator</institution>, Boston, MA</aff>
</contrib-group>
<author-notes>
<fn id="n1"><label>&#x002A;</label><p>and</p></fn>
<fn id="n2" fn-type="equal"><label>&#x002A;&#x002A;</label><p>contributed equally</p></fn>
<corresp id="cor1"><label>&#x0023;</label><bold>Corresponding Author:</bold> Sara Suliman, MPH, PhD, Division of Rheumatology, Inflammation and Immunity, Brigham and Women&#x2019;s Hospital, Boston MA. Diagnostics Accelerator Working Group and Laboratory of the Mass General and Brigham Center for COVID Innovation (MGBCCI), 149 Navy Yard room: 4325, Charlestown MA, USA. Email: <email>ssuliman1@bwh.harvard.edu</email></corresp>
<fn id="n3"><p><bold>Author&#x2019;s Contributions:</bold> BAT, SEK, RRK, BCC and SS wrote the first draft of the manuscript</p>
<p>BAT, SEK, and KG led the project management, volunteer coordination and lab operations</p>
<p>BAT, SEK, BCC, PK and LR established the MGB Diagnostics Accelerator lab, acquired samples and established biosafety and IRB protocols</p>
<p>SS, SM, SJ, DS, PJ, CER developed evaluation protocols</p>
<p>SS and LR managed the MGB COVID Diagnostics Accelerator lab</p>
<p>BAT and RRK led sample and data management</p>
<p>RRK and BCC led the analysis and data interpretation</p>
<p>RA, JT and GM corresponded with LFA providers and down-selected assays for evaluation</p>
<p>CER, BN, EP, SEK, BAT, EW, LE, CK, AB, BF, HV, WZ, SP, MK, JK, JT, AH, RA, RL, HP, NL, CS, UP, PD, SZ, ZG, VD, GW, RB, JW, PC, SB, CMS volunteered in the MGB COVID Diagnostics Accelerator lab</p>
<p>YK, TS and RRK developed the interactive web app for interpretation of test results DW led the Diagnostics Pillar of the Mass General Brigham COVID Center for Innovation</p>
<p>All authors planned and/or performed experiments, edited and approved the final version of the manuscript</p></fn>
<fn id="n4"><p><bold>Funding:</bold> This study was funded by a grant from the Massachusetts Consortium for Pathogen Readiness (MassCPR).</p></fn>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.01.02.20248998</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>1</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>02</day>
<month>1</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>1</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), CC BY-NC 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="20248998.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<sec>
<title>Background</title>
<p>COVID-19 has resulted in significant morbidity and mortality worldwide. Lateral flow assays can detect anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) antibodies to monitor transmission. However, standardized evaluation of their accuracy and tools to aid in interpreting results are needed.</p></sec>
<sec>
<title>Methods</title>
<p>We evaluated 20 IgG and IgM assays selected from available tests in April 2020. We evaluated the assays&#x2019; performance using 56 pre-pandemic negative and 56 SARS-CoV-2-positive plasma samples, collected 10-40 days after symptom onset, confirmed by a molecular test and analyzed by an ultra-sensitive immunoassay. Finally, we developed a user-friendly web app to extrapolate the positive predictive values based on their accuracy and local prevalence.</p></sec>
<sec>
<title>Results</title>
<p>Combined IgG&#x002B;IgM sensitivities ranged from 33.9&#x0025; to 94.6&#x0025;, while combined specificities ranged from 92.6&#x0025; to 100&#x0025;. The highest sensitivities were detected in Lumiquick for IgG (98.2&#x0025;), BioHit for both IgM (96.4&#x0025;), and combined IgG&#x002B;IgM sensitivity (94.6&#x0025;). Furthermore, 11 LFAs and 8 LFAs showed perfect specificity for IgG and IgM, respectively, with 15 LFAs showing perfect combined IgG&#x002B;IgM specificity. Lumiquick had the lowest estimated limit-of-detection (LOD) (0.1 &#x03BC;g/mL), followed by a similar LOD of 1.5 &#x03BC;g/mL for CareHealth, Cellex, KHB, and Vivachek.</p></sec>
<sec>
<title>Conclusion</title>
<p>We provide a public resource of the accuracy of select lateral flow assays with potential for home testing. The cost-effectiveness, scalable manufacturing process, and suitability for self-testing makes LFAs an attractive option for monitoring disease prevalence and assessing vaccine responsiveness. Our web tool provides an easy-to-use interface to demonstrate the impact of prevalence and test accuracy on the positive predictive values.</p></sec>
</abstract>
<kwd-group kwd-group-type="author">
<title>Key words</title>
<kwd>SARS-CoV2</kwd>
<kwd>Coronavirus</kwd>
<kwd>antibodies</kwd>
<kwd>COVID-19</kwd>
<kwd>lateral flow assays</kwd>
</kwd-group>
<counts>
<page-count count="43"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>D.R.W. has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the Simoa technology and a founder of the company and also serves on its Board of Directors. D.R.W.s interests were reviewed and are managed by Brigham and Womens Hospital and Partners HealthCare in accordance with their policies on competing interests. The assays in this publication have been licensed by Brigham and Womens Hospital to Quanterix Corporation. M.N., T.G. and D.R.W. have filed intellectual property on the technology described in this manuscript.</p></notes>
<notes notes-type="clinical-trial-statement">
<title>Clinical Trial</title><p>The study used biobanked samples to evaluate serological tests for COVID-19. We did not apply any intervention to the study participants.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>The study is supported by funding from the Massachusetts Consortium on Pathogen Readiness (MassCPR)</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>The study was approved under the Massachusetts General Brigham (MGB) Institutional Review Board (protocol no. 2020P001204)</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Coronavirus disease 2019 (COVID-19), caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a global pandemic on March 11<sup>th</sup>, 2020<sup><xref ref-type="bibr" rid="c1">1</xref></sup>. A second wave of the pandemic is well underway<sup><xref rid="c1" ref-type="bibr">1</xref>, <xref rid="c2" ref-type="bibr">2</xref>, <xref rid="c3" ref-type="bibr">3</xref>, <xref rid="c4" ref-type="bibr">4</xref></sup>. However, accurate estimates of transmission rely on accurate and widely available immunosurveillance tools to measure SARS-CoV-2 infection in diverse community settings. Among SARS-CoV-2-infected individuals, 40-45&#x0025; are estimated to remain asymptomatic<sup><xref ref-type="bibr" rid="c5">5</xref></sup>, suggesting that prevalence is likely underestimated<sup><xref ref-type="bibr" rid="c6">6</xref></sup>. Therefore, detecting prior exposure to SARS-CoV-2 as opposed to other viruses, including other coronaviruses is crucial<sup><xref ref-type="bibr" rid="c7">7</xref></sup>.</p>
<p>There are different types of clinical SARS-CoV-2 tests<sup><xref ref-type="bibr" rid="c8">8</xref></sup>. Diagnostic testing relies on reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR) and antigen-based immunodiagnostics to detect active infection<sup><xref ref-type="bibr" rid="c9">9</xref>, <xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c11">11</xref></sup>. Conversely, serological tests can monitor population prevalence and prior exposure by measuring antibodies against SARS-CoV-2<sup><xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c14">14</xref></sup>. These include enzyme-linked immunosorbent assays (ELISAs), chemiluminescence assays, and lateral flow assays (LFAs)<sup><xref ref-type="bibr" rid="c11">11</xref>, <xref ref-type="bibr" rid="c15">15</xref>, <xref ref-type="bibr" rid="c16">16</xref></sup>. LFAs are attractive for home testing and population surveillance, since they are affordable, scalable, rely on easily accessible specimens such as fingerstick whole blood and give a result readout within minutes<sup><xref ref-type="bibr" rid="c13">13</xref></sup>. Since multiple vaccines received emergency use authorization<sup><xref ref-type="bibr" rid="c17">17</xref></sup>, LFAs could be used to determine whether vaccines elicit a detectable and durable immune response<sup><xref rid="c18" ref-type="bibr">18</xref>, <xref rid="c19" ref-type="bibr">19</xref>, <xref rid="c20" ref-type="bibr">20</xref>, <xref rid="c21" ref-type="bibr">21</xref>, <xref rid="c22" ref-type="bibr">22</xref></sup>. Furthermore, early seroconversion was shown to predict better clinical outcomes<sup><xref ref-type="bibr" rid="c23">23</xref>, <xref ref-type="bibr" rid="c24">24</xref></sup>. Hence, easy-to-use LFAs will have important applications in the upcoming phases of the pandemic. Since the onset of the COVID-19 epidemic, multiple studies evaluated the accuracy of serological tests<sup><xref rid="c15" ref-type="bibr">15</xref>, <xref rid="c25" ref-type="bibr">25</xref>, <xref rid="c26" ref-type="bibr">26</xref>, <xref rid="c27" ref-type="bibr">27</xref>, <xref rid="c28" ref-type="bibr">28</xref>, <xref rid="c29" ref-type="bibr">29</xref></sup>. Many of these tests received Emergency Use Authorization (EUA) through the Food and Drug Administration (FDA)<sup><xref ref-type="bibr" rid="c30">30</xref></sup>.</p>
<p>Despite the utility of SARS-CoV2 antibody tests, misinterpretation of results is very likely<sup><xref ref-type="bibr" rid="c31">31</xref></sup>. A negative serological test result does not preclude prior infection since seroconversion occurs 9-11 days after symptoms onset for IgM and 18-20 days for IgG antibodies, respectively<sup><xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c32">32</xref>, <xref ref-type="bibr" rid="c33">33</xref>, <xref ref-type="bibr" rid="c34">34</xref></sup>. Conversely, positive results do not indicate active infection<sup><xref ref-type="bibr" rid="c31">31</xref></sup>. Furthermore, the prevalence of SARS-CoV-2 is highly variable <sup><xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c6">6</xref></sup>, and known to directly impact the predictive value of a test result. A higher prevalence increases the likelihood that positive test results indicate a real infection (i.e. higher positive predictive value)<sup><xref ref-type="bibr" rid="c35">35</xref></sup>, but will also decrease the negative predictive value, resulting in more false negative results<sup><xref ref-type="bibr" rid="c35">35</xref></sup>. Therefore, accessible tools to assist the public with interpreting results based on test accuracy and different prevalence scenarios are critical<sup><xref ref-type="bibr" rid="c31">31</xref>, <xref ref-type="bibr" rid="c36">36</xref></sup>.</p>
<p>In April 2020, the Mass General Brigham Center (MGB) for COVID Innovation&#x2019;s direct-to-consumer working group scanned available serological assays and selected 20 lateral flow assays, based on reported assay characteristics and supply chain availability<sup><xref ref-type="bibr" rid="c37">37</xref></sup>. The LFAs were evaluated by blinded operators using the same samples to standardize the evaluation of their accuracy. Additionally, we developed a user-friendly web-tool to provide context for the end user to interpret their results. Here, we report the evaluation data to serve as a public resource to guide implementation of LFAs, and the tool to aid the interpretation of home testing results.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<sec id="s2a">
<title>Sample procurement</title>
<p>We procured 56 SARS-CoV-2 positive, 46 pre-pandemic negative, and 10 HIV&#x002B; EDTA plasma samples. SARS-CoV-2 positive EDTA plasma samples were obtained from clinical discards banked within 24-72 hours of collection at the Crimson Core of the MGB Biobank from hospitalized symptomatic patients. All samples had positive SARS-CoV-2 PCR results using an EUA approved test at the Brigham and Women&#x2019;s Hospital (Panther Fusion SARS-CoV-2 assay, Hologic, Inc., San Diego, CA or Xpert Xpress SARS-CoV-2, Cepheid, Inc., Sunnyvale, CA) or the Clinical Research Sequencing Platform at the Broad Institute of MIT and Harvard (in house Laboratory Developed Test) 10-40 days prior to sample collection. The participants&#x2019; charts were reviewed by study staff to identify samples collected &#x2265;10 days after onset of symptoms and to exclude immunosuppressed participants, after which samples were anonymized and stripped of protected health information. Pre-pandemic negative control samples were randomly selected from healthy participants with a Charlson Age-Comorbidity Index<sup><xref ref-type="bibr" rid="c38">38</xref></sup> score &#x2264;2, with EDTA plasma banked in the MGB Biobank between Jan 1-Dec 1, 2019 from inpatients. HIV-positive control samples were obtained from EDTA plasma samples banked prior to January 2020 in a study on neuropathic pain in HIV. All HIV-positive participants were on antiretroviral therapy. For 8 out of the 10 HIV-positive samples, viral load quantification was available and showed 256 copies/ml or less, and 5 showed either undetectable loads or under 20 copies/ml. The study was approved under the Massachusetts General Brigham (MGB) Institutional Review Board (protocol no. 2020P001204).</p>
</sec>
<sec id="s2b">
<title>Lateral Flow Assays (LFAs)</title>
<p>Twenty commercial IgG/IgM lateral flow assays (LFAs) from 18 manufacturers were evaluated <bold>(<xref rid="tblS1" ref-type="table">Supplementary Table 1</xref>)</bold>. LFAs were analyzed by blinded operators according to manufacturer instructions for use (IFU), with the exception of using micropipettes instead of manufacturer-provided droppers to minimize technical variability. Samples were thawed on ice, randomized, and brought to room temperature. Kit components were also brought to room temperature. The IFU-specified volumes of sample and buffer were added to the cassette. Specified sample volumes varied for different LFAs but were typically in the 5-20&#x03BC;L range. The cassettes were run at room temperature on a flat surface and results read immediately after the time interval defined in the IFU (typically ranging from 10-15 minutes). Each cassette was independently scored by two blinded raters as either &#x201C;positive,&#x201D; &#x201C;negative,&#x201D; or &#x201C;invalid&#x201D;. Ratings were designated according to the interpretation guidelines outlined in each individual IFU. Each cassette was photographed under four standardized illumination conditions and viewpoints for future analysis.</p>
</sec>
<sec id="s2c">
<title>Reproducibility testing</title>
<p>For inter-operator reproducibility analysis, separate pools of EDTA plasma were obtained from &#x003E;30 pre-pandemic healthy individuals (negative pool) and &#x003E;30 convalescent participants collected after symptom resolution at the Massachusetts General Hospital (MGH) respiratory illness clinic (positive pool). Convalescent samples for the positive pool were confirmed to be positive using the COBAS SARS-CoV-2 PCR test (Roche Diagnostics, Indianapolis, IN) at MGH. A total of 20 replicates per pool were run by two independent pairs of blinded operators, alternating between positive and negative pools (10 replicates per pair). Reproducibility was calculated according to agreement between operator ratings as well as concordance of readout with sample pool COVID status.</p>
</sec>
<sec id="s2d">
<title>Sensitivity and specificity testing</title>
<p>Our cohort of 112 EDTA plasma samples was used across all 20 LFAs to evaluate performance: sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Samples were sub-aliquoted throughout the analysis to minimize freeze-thaw cycles. Binary presence/absence were used, and discordant calls were resolved by a third operator inspecting photographs taken of the relevant LFA.</p>
</sec>
<sec id="s2e">
<title>LFA usability</title>
<p>In addition to initial screening <sup><xref ref-type="bibr" rid="c37">37</xref></sup>, each LFA kit was assessed for consumer usability based on complexity of kit materials, sample requirements, and IFU clarity. Supplied kit components were documented for completeness and examined for ease-of-use. IFU protocols were rated on a scale from 0-14 according to a predefined rubric <bold>(<xref rid="tblS2" ref-type="table">Supplementary Table 2</xref>)</bold> by three independent raters. Usability evaluations are shown in <bold><xref rid="tblS3" ref-type="table">Supplementary Table 3</xref></bold>. Sample input requirements for each LFA are in <bold><xref rid="tblS1" ref-type="table">Supplementary Table 1</xref></bold>.</p>
</sec>
<sec id="s2f">
<title>Ultrasensitive Simoa Serology Assays</title>
<p>Plasma samples were diluted 4000-fold, and the total IgG and IgM levels against the SARS-CoV2 spike protein were measured using a custom Single Molecule Array (Simoa) assay as described<sup><xref ref-type="bibr" rid="c39">39</xref></sup> on an automated HD-X Analyzer (Quanterix, Billerica, MA, USA), to provide a quantitative reference for anti-spike antibody titers in the plasma samples. Normalized mean Average Enzymes per Bead (AEB) levels were calculated using a standard set of calibrators produced by serially diluting a large volume of plasma from seroconverted individuals. Antibody concentrations were estimated using a calibration curve of recombinant anti-SARS-CoV-2 antibodies<sup><xref ref-type="bibr" rid="c40">40</xref></sup>.</p>
</sec>
<sec id="s2g">
<title>Analysis and Webapp</title>
<p>Detailed methods are in the supplementary.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Study Population</title>
<p>We obtained plasma samples from 56 pre-pandemic patients, including 10 HIV&#x002B;, and 56 symptomatic patients in March and April 2020. HIV-negative samples were matched for sex and age between the COVID- and COVID&#x002B; groups. The overall study population included 25.9&#x0025; Blacks, 4.5&#x0025; Latinx, 9.8&#x0025; Asian and 43.8&#x0025; Non-Hispanic Whites <bold>(<xref rid="tbl1" ref-type="table">Table 1</xref>)</bold>. COVID&#x002B; samples were from individuals between 10-40 days post symptom onset, with 60.7&#x0025; samples taken between 2-4 weeks. Of all the COVID&#x002B; participants, 7 (12.5&#x0025;) were symptomatic outpatients and 49 (87.5&#x0025;) were hospitalized. Among those hospitalized, 25 (51&#x0025;) required intensive care unit (ICU) treatment and 4 (8.2&#x0025;) were deceased at the time of chart review <bold>(<xref rid="tbl2" ref-type="table">Table 2</xref>)</bold>. Additional mortalities were possible after chart review since some participants were in critical condition in the ICU.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1:</label>
<caption><p>Demographic information of all individuals whose plasma samples were used for this study. Individuals are broken out by COVID&#x002B;/- and HIV&#x002B;/- status. Black includes one mixed African American in the COVID-HIV&#x002B; group.</p></caption>
<graphic xlink:href="20248998v1_tbl1.tif"/>
</table-wrap>
<table-wrap id="tbl2" orientation="portrait" position="float">
<label>Table 2:</label>
<caption><p>Clinical information for the COVID-positive individuals whose plasma was used in this study. Individuals are broken out by the number of days between symptom onset and blood collection.</p></caption>
<graphic xlink:href="20248998v1_tbl2.tif"/>
</table-wrap>
</sec>
<sec id="s3b">
<title>LFA Performance: Reproducibility</title>
<p>Four independent operators working in teams of two on separate days applied each pool 10 times to each LFA, with processing as dictated by the instructions for use (IFU). API version1 LFAs were not assessed for reproducibility due to limited cassette availability and high sample volumes required. Of the remaining 19 LFAs, three (BTNX, Camtech, and Carehealth) had 100&#x0025; consistent correct outcomes across both isotypes, with an additional three (BioHit, Zhuhai Livzon, and Phamatech) having no incorrect or inconsistent outcomes with one or two invalid tests <bold>(<xref rid="fig1" ref-type="fig">Figure 1</xref>)</bold>. IgG was the more reproducible isotype. The majority of incorrect consistent calls came from operators calling a COVID&#x002B; sample IgM negative <bold>(<xref rid="fig1" ref-type="fig">Figure 1</xref>)</bold>.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1:</label>
<caption><title>LFA reproducibility.</title>
<p>Colors represent LFA outcome performed across two days (A &#x0026; B) by two independent pairs of operators on a COVID positive (COVID&#x002B;) pooled sample and a COVID negative (COVID-) pooled sample. On each day, ten technical replicates of each pool were performed. Blue represents replicates where both operators that day agreed on the outcome, and the outcome was correctly called positive or negative. Red represents occasions where both operators agreed, but the outcome was incorrectly called. Orange represents replicates where the operators did not agree on the LFA outcome. Light yellow represents an invalid test where control bands did not meet criteria for a valid test. IgG was the most reproducible isotype for all LFAs except Oranoxis, and consistent false negatives were common occurrences for IgM for the majority of LFAs.</p></caption>
<graphic xlink:href="20248998v1_fig1.tif"/>
</fig>
</sec>
<sec id="s3c">
<title>LFA Performance: Practicalities of Use</title>
<p>We assessed the LFAs according to this rubric <bold>(<xref rid="tblS2" ref-type="table">Supplementary Table 2</xref>)</bold> by three independent raters and assigned a composite score on a scale of 0-14 <bold>(<xref rid="tblS3" ref-type="table">Supplementary Table 3</xref>)</bold>. Five LFAs (BioHit, InTec, Lumiquick, Phamatech, and U2U) received full marks for IFU clarity. LFAs frequently lost points for imprecise instructions regarding correct usage of disposable droppers as well as optimal time between adding sample and reading the results. Important kit usability criteria, such as whether the included pipette droppers show clear volume markings, were also recorded <bold>(<xref rid="tblS3" ref-type="table">Supplementary Table 3</xref>)</bold>. While these kits may not yet be intended for the general public, it will be important to clarify the instructions moving forward and include clearly marked droppers to minimize potential for sample volume errors.</p>
</sec>
<sec id="s3d">
<title>LFA Performance: Sensitivity and Specificity</title>
<p>To focus on LFA specificity, given the likely use of these tests in low-prevalence settings, disagreement between operators was interpreted as a negative call. Across all but three of the LFAs (Biohit, BTNX, Vivacheck), sensitivity was higher for IgG than IgM. Sensitivity for IgG ranged from 98.2&#x0025; (Lumiquick) down to 72.7&#x0025; (Oranoxis), and for IgM from 96.4&#x0025; (BioHit) to 23.2&#x0025; (Oxo and U2U) <bold>(<xref rid="tbl3" ref-type="table">Table 3</xref>)</bold>. LFA specificity was much higher for both isotypes, with 11 LFAs having a specificity of 100&#x0025; for IgG (API, API v2, BTNX, Camtech, Genobio, Oranoxis, Phamatech, Ray Biotech, Ray Biotech_v2, U2U and Zhuhai Livzon), and 8 LFAs having a specificity of 100&#x0025; for IgM (API, CareHealth, Cellex, Lumiquick, Oranoxis, Ray Biotech v2, U2U, Zhuhai Livzon) <bold>(<xref rid="tbl3" ref-type="table">Table 3</xref>)</bold>. Under the assumption that the likelihood of two randomly occurring false positives for any one individual is low, an IgG/IgM composite score (averaged operator scores, see Methods) was produced to maximize test specificity. Using this composite score, all LFAs except BioHit, Cellex, Edinburgh, InTec and Vivachek achieved a specificity of 100&#x0025;. This result underscores the potential of considering the outcome in both isotypes to minimize false positives, although it is more likely that a single isotype will be used in clinical testing.</p>
<table-wrap id="tbl3" orientation="portrait" position="float">
<label>Table 3:</label>
<caption><p>LFA performance in terms of sensitivity and specificity. N: Total number of valid assays; TP: True Positive; TN: True Negative; FP: False Positive; FN: False Negative; PPV: Positive Predictive Value; NPV: Negative Predictive Value; and CI95: 95&#x0025; confidence interval.</p></caption>
<graphic xlink:href="20248998v1_tbl3.tif"/>
<graphic xlink:href="20248998v1_tbl3a.tif"/>
</table-wrap>
<p>We created heatmaps to visualize individual sample outcomes across all LFAs to assess whether we systematically detected the same miscalls across multiple LFAs <bold>(<xref rid="fig2" ref-type="fig">Figure 2</xref>)</bold>. False negatives (blue squares in the COVID&#x002B; panel) amongst COVID&#x002B; patients were somewhat reproducible, with three COVID&#x002B; samples called negative in both isotypes by all or all but one LFA. These miscalls were not clearly explained by known demographics (age, sex) or clinical variables (disease severity, weeks post symptom onset) <bold>(<xref rid="fig2" ref-type="fig">Figure 2</xref></bold>, bottom panel<bold>)</bold>. To investigate whether these miscalls were related to low titers of anti-SARS-CoV-2 antibodies from participants with a suppressed immune response, all 112 samples were analyzed for anti-spike IgG and IgM antibodies using a custom quantitative Simoa assay<sup><xref ref-type="bibr" rid="c39">39</xref></sup>. The three samples that were called negative across almost all LFAs, which were collected 2-3 weeks after symptoms onset, had the lowest levels of anti-spike antibodies in COVID&#x002B; samples for both IgG and IgM, suggesting these participants had slower or suppressed immune responses to SARS-CoV-2 infection.</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2:</label>
<caption><title>Per-individual LFA performance.</title>
<p>Colors represent scores computed for IgG (top panel) and IgM (lower panel), where dark red=&#x002B;1 (operators all agree a band is present) and dark blue=-1 (operators all agree there is no band) with intermediate colors (pink and light blue) representing varying degrees of operator disagreement. Grey represents invalid runs. Samples are ordered within the COVID-HIV-, COVID-HIV&#x002B;, and COVID&#x002B; (all HIV-) groups in order of decreasing average score across all LFAs for both antibodies. Clinical variables include age (&#x003C;50yrs: light blue, 50-69yrs: intermediate blue, &#x2265;70yrs: dark blue), sex (blue: male, pink: female), disease severity (hospitalized: light green, ICU: orange, ICU&#x002B;respirator: red, deceased: black), and weeks post symptom-onset (dark green: 1-2 weeks, lightest green: &#x2265;5 weeks).</p></caption>
<graphic xlink:href="20248998v1_fig2.tif"/>
</fig>
<p>Unlike false negatives, most false positives <bold>(<xref rid="fig2" ref-type="fig">Figure 2</xref></bold>, red squares in COVID-panel<bold>)</bold> amongst COVID-individuals appear largely uncorrelated between LFAs. However, two samples showed IgG false positives across multiple LFAs, which may suggest long lasting antibodies from exposure to coronaviruses other than SARS-CoV-2. Nonetheless, this observation is not reflected in the antibody levels from the Simoa analysis, which showed barely detectable anti-spike antibodies in these two samples.</p>
</sec>
<sec id="s3e">
<title>Defining the limit of detection for qualitative LFAs</title>
<p>The custom Simoa anti-spike IgG and IgM antibody assays use a standard curve to determine standardized antibody concentration in each sample<sup><xref ref-type="bibr" rid="c39">39</xref></sup>. The results obtained from this assay can therefore be used to estimate a limit of detection (LOD) for each of the qualitative LFAs. The cumulative number of false negative LFA calls in COVID&#x002B; samples <bold>(<xref rid="fig3" ref-type="fig">Figure 3</xref>, y-axis)</bold> were computed as a function of decreasing antibody concentrations <bold>(<xref rid="fig3" ref-type="fig">Figure 3</xref>, x-axis)</bold> separately for IgG and IgM. We define the LOD for each LFA/antibody as the concentration at which &#x2265;95&#x0025; of the COVID&#x002B; samples are called unambiguously positive <bold>(<xref rid="tblS4" ref-type="table">Supplementary table 4</xref>)</bold>. Using this definition, for IgG, all LFAs (except Genobio, Oranoxis, OZO, Ray Biotech, and U2U) have an LOD within the linear range of the SIMOA assay (1 - 10,000 &#x03BC;g/mL). Lumiquick has the lowest LOD at 0.1 &#x03BC;g/mL, which was extrapolated by dilution to be within the linear range of the Simoa standards, and CareHealth, Cellex, KHB and Vivachek all have an LOD of 1.5 &#x03BC;g/mL <bold>(<xref rid="tblS4" ref-type="table">Supplementary table 4</xref>)</bold>. Considering the generally lower sensitivity observed with the IgM assays <bold>(<xref rid="fig2" ref-type="fig">Figure 2</xref>)</bold>, IgM assays consistently have higher LODs, with 9 exceeding 1,000 &#x03BC;g/mL. BioHit has the lowest IgM LOD at 0.6 &#x03BC;g/mL, and API version2, BTNX, CareHealth and Vivachek all have LODs under 10 &#x03BC;g/mL.</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3:</label>
<caption><title>Determining the limit of detection of qualitative LFAs.</title>
<p>Samples were ranked from highest concentration of anti-spike antibody (determined by Simoa) on the right, to lowest concentration (x-axis). As the sample concentration decreases to the left, a cumulative count of false negatives is shown on the y-axis. IgG is shown on the left, IgM on the right. Note the difference in magnitude of the y-axes between IgG and IgM; these LFAs are generally more sensitive to IgG than IgM.</p></caption>
<graphic xlink:href="20248998v1_fig3.tif"/>
</fig>
</sec>
<sec id="s3f">
<title>Interpreting test positivity with low prevalence in the general population</title>
<p>Low prevalence places a high burden on specificity<sup><xref ref-type="bibr" rid="c35">35</xref></sup>. Given the high proportion of true negative individuals in the population being studied, prevalence increases the ratio of false positive to true positive test outcomes<sup><xref ref-type="bibr" rid="c41">41</xref></sup>. Positive predictive values (PPV) correspond to the likelihood that a positive test result reflect true positivity as measured by a gold standard PCR result. We computed PPVs as a function of the cumulative fraction of the population infected with (and assumed to have produced antibodies to) SARS-CoV-2 <bold>(<xref rid="fig4" ref-type="fig">Figure 4</xref>)</bold>. Here we see that even with the conservative interpretation of LFA outcome (requiring the majority of operators to see a band to call a sample positive for either IgG or IgM), when the population seroprevalence is &#x223C;5&#x0025; the PPV for these assays spans a large range (from &#x223C;30&#x0025; to 100&#x0025;). As the population prevalence increases, the burden on specificity is decreased, and at 50&#x0025; prevalence the PPV of all LFAs is above 87.5&#x0025;. Posterior PPV can be improved for most LFAs by requiring both IgG and IgM to be read as positive in order to count an individual as positive <bold>(<xref rid="fig4" ref-type="fig">Figure 4</xref>, right panels)</bold>.</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4:</label>
<caption><p><bold>Effect of a changing disease prevalence (x axis) on the population-level PPV of each test</bold> for scores derived from IgG (left), IgM (middle), and the average score of both antibodies (right). As disease prevalence increases, the high burden on specificity of LFAs is reduced. Color coding: Grey: no improvement; Light blue: rescues one of the two antibodies; Dark blue: rescues both of the antibodies; Orange: performs worse than one of the antibodies.</p></caption>
<graphic xlink:href="20248998v1_fig4.tif"/>
</fig>
<p>To visualize the effect of changing population prevalence on the PPV, we created an interactive webapp <bold>(</bold><ext-link ext-link-type="uri" xlink:href="https://covid.omics.kitchen">https://covid.omics.kitchen</ext-link>; <bold><xref rid="fig5" ref-type="fig">Figure 5</xref>)</bold>, which allows the user to extrapolate the likelihood that they do in fact have SARS-CoV-2 antibodies if they have a positive LFA result, given the infection prevalence and test accuracy. The app includes benchmark performance of all 20 LFAs evaluated here, as well as those reported in Whitman et al<sup><xref ref-type="bibr" rid="c16">16</xref></sup> (filtered to remove samples taken under 10 days post symptom-onset). In an effort to further generalize the utility of this tool, we allow the user to explore the effects of assay performance under difference prevalence scenarios, and to input the reported prevalence data from specific geographic locations within the US<sup><xref ref-type="bibr" rid="c1">1</xref></sup>, based on national, state, and county records.</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Figure 5:</label>
<caption><p><bold>Example image of the interactive webapp</bold> hosted at <ext-link ext-link-type="uri" xlink:href="https://covid.omics.kitchen">https://covid.omics.kitchen</ext-link>. Using the sliders, one is able to visualize the effect of changing the disease prevalence (and the test performance) on the resulting probability that, given a positive LFA test, the individual does in fact have SARS-CoV-2 antibodies. The figure shows an example of positive predictive value using the US national prevalence of 5&#x0025; (on November 27<sup>th</sup>, 2020) and the performance characteristics of the InTec LFA.</p></caption>
<graphic xlink:href="20248998v1_fig5.tif"/>
</fig>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>In this study, we report a standardized cross-evaluation of LFAs on the same pre-pandemic SARS-CoV-2-negative and PCR-confirmed SARS-CoV-2-positive samples, and rate their reproducibility, usability, and performance characteristics. Overall, the LFAs showed a higher propensity for false negative than false positive readings. Results are public: <ext-link ext-link-type="uri" xlink:href="https://covidinnovation.partners.org/evaluation/">https://covidinnovation.partners.org/evaluation/</ext-link>. We use the Simoa technology<sup><xref ref-type="bibr" rid="c39">39</xref></sup> to measure the concentrations of anti-spike protein IgG and IgM antibodies and extrapolate the assays&#x2019; limits of detection. We also established a web tool to aid users in understanding the likelihood they have anti-SARS-CoV-2 antibodies given a positive test result. This resource of performance characteristics of several LFAs and a tool for result interpretation, can both be used for immunosurveillance and future home testing applications.</p>
<p>LFAs are tractable tools to estimate community seroprevalence, especially with anticipated seasonal fluctuations in the transmission dynamics of SARS-CoV-2 and other viruses that cause the common cold, which confound the symptomatologic diagnosis of COVID-19<sup><xref ref-type="bibr" rid="c42">42</xref></sup>. As new waves of the COVID-19 pandemic resurge around the globe<sup><xref ref-type="bibr" rid="c1">1</xref></sup>, and with commencing vaccinations against SARS-CoV-2 infections<sup><xref ref-type="bibr" rid="c18">18</xref>, <xref ref-type="bibr" rid="c19">19</xref>, <xref ref-type="bibr" rid="c20">20</xref>, <xref ref-type="bibr" rid="c22">22</xref></sup>, there is a renewed interest in serological tests to detect anti-SARS-CoV-2 antibodies<sup><xref ref-type="bibr" rid="c28">28</xref>, <xref ref-type="bibr" rid="c43">43</xref></sup>. Affordable LFAs offer an attractive option for monitoring the presence and longevity of anti-SARS-CoV-2 antibodies, and determining population-level herd immunity<sup><xref ref-type="bibr" rid="c44">44</xref></sup>. LFAs also obviate the need for complex laboratories to process the samples<sup><xref ref-type="bibr" rid="c45">45</xref></sup>. As the pandemic expands to previously unexposed communities, it is critical to use simple tools to monitor exposure dynamics and seroconversion in SARS-CoV-2-exposed individuals, as well as vaccine-induced immunity<sup><xref ref-type="bibr" rid="c22">22</xref></sup>. We tested a mixture of LFAs targeting SARS-CoV2 nucleocapsid, spike proteins, or both. Moderna&#x2019;s mRNA-1273 and Pfizer-BioNTech COVID-19 vaccines encode SARS-CoV2 spike proteins to induce anti-spike antibodies<sup><xref ref-type="bibr" rid="c20">20</xref>, <xref ref-type="bibr" rid="c46">46</xref></sup>. Therefore, LFAs targeting the spike and nucleocapsid proteins of SARS-CoV2 could be used to differentiate vaccine- and infection-induced antibody responses, respectively.</p>
<p>Rigorous evaluation of these LFAs by manufacturer-independent parties is important. The US FDA independently reviews medical products before commercialization. The FDA used Emergency Use Authorization (EUA) authority to accelerate the implementation of diagnostic products during the pandemic. Commercial manufacturers were required to submit a completed EUA request<sup><xref ref-type="bibr" rid="c30">30</xref></sup>. Unfortunately, the rush to market introduced many tests that did not meet typical US or international standards<sup><xref ref-type="bibr" rid="c47">47</xref></sup>. Therefore, the FDA and international regulatory agencies continue to update guidelines for authorization of new serological tests. Our evaluation plan mirrored the FDA guidelines for evaluating serological tests<sup><xref ref-type="bibr" rid="c30">30</xref></sup>. We included 10 HIV-positive samples to test whether they have higher false positive results in SARS-CoV2-negative samples<sup><xref ref-type="bibr" rid="c48">48</xref></sup>, and did not detect higher false positive results.</p>
<p>The mere detection of IgG or IgM responses does not guarantee that neutralizing antibodies are present at protective titers <sup><xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c49">49</xref></sup>. The study demographics suggest a slight over-representation of African Americans among cases, as reported<sup><xref ref-type="bibr" rid="c50">50</xref></sup>. However, the sample size was underpowered to formally determine the effect of race on test performance. In our analysis, IgM detectability was less sensitive and reproducible than IgGs across multiple LFAs, possibly due to both lower IgM titres, and lower limits of detection for the assays. Waning antibody responses have been reported in some SARS-CoV-2-infected individuals<sup><xref ref-type="bibr" rid="c51">51</xref>, <xref ref-type="bibr" rid="c52">52</xref>, <xref ref-type="bibr" rid="c53">53</xref>, <xref ref-type="bibr" rid="c54">54</xref></sup>. Furthermore, reported cases of re-infection with SARS-CoV-2 suggest that prior exposure, and even seroconversion, do not universally protect against SARS-CoV-2 infection<sup><xref ref-type="bibr" rid="c54">54</xref>, <xref ref-type="bibr" rid="c55">55</xref>, <xref ref-type="bibr" rid="c56">56</xref></sup>. This could result from low antibody titers as shown in an immunocompromised patient<sup><xref ref-type="bibr" rid="c57">57</xref></sup>, low durability of infection-induced antibodies<sup><xref ref-type="bibr" rid="c52">52</xref>, <xref ref-type="bibr" rid="c53">53</xref>, <xref ref-type="bibr" rid="c54">54</xref></sup>, or low neutralizing potential of SARS-CoV-2 antibodies in some individuals<sup><xref ref-type="bibr" rid="c44">44</xref></sup>. IgG and IgM antibodies may also target irrelevant epitopes outside the spike and receptor binding domains, and consequently be less efficient at intercepting infection by the virus<sup><xref ref-type="bibr" rid="c58">58</xref></sup>. The WHO cautions against interpreting presence of antibodies, even neutralizing ones, as lower risk of re-infection and transmission<sup><xref ref-type="bibr" rid="c59">59</xref></sup>. The presence of antibodies could, however, be used for rapid immunosurveillance to monitor extent of population transmission, particularly in asymptomatic but SARS-CoV2-exposed individuals<sup><xref ref-type="bibr" rid="c6">6</xref>, <xref ref-type="bibr" rid="c43">43</xref></sup>.</p>
<p>One major concern about the deployment of these tests is the misinterpretation of positive results<sup><xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c49">49</xref></sup>. As more tests move towards FDA clearance for home use, clear scientific communication about the result interpretation becomes more crucial<sup><xref rid="c31" ref-type="bibr">31</xref>,</sup> 49. A positive serological result does not necessarily mean active infection<sup><xref ref-type="bibr" rid="c31">31</xref>, <xref ref-type="bibr" rid="c41">41</xref>, <xref ref-type="bibr" rid="c60">60</xref></sup>. Although combined use of molecular and seroconversion results can be used to confirm the diagnosis of symptomatic and hospitalized individuals<sup><xref ref-type="bibr" rid="c45">45</xref></sup>, a positive serological test in the absence of symptoms dissociates the presence of the antibodies from the time of infection<sup><xref ref-type="bibr" rid="c54">54</xref></sup>. Additionally, it is important to understand the implication of false positive and false negative results, particularly in the context of a low-prevalence disease such as COVID-19<sup><xref ref-type="bibr" rid="c35">35</xref></sup>. Low prevalence decreases the negative predictive value of a test, but increases the rate of false positives<sup><xref ref-type="bibr" rid="c35">35</xref></sup>. A false positive serological test result may prematurely instill confidence that one has immunity against SARS-CoV-2 infection, thus resulting in behavioral changes that increase risk of transmission<sup><xref ref-type="bibr" rid="c61">61</xref></sup>. Hence, the probability that a person without antibodies will test negative on a serological test is more important than test sensitivity<sup><xref ref-type="bibr" rid="c59">59</xref>, <xref ref-type="bibr" rid="c60">60</xref>, <xref ref-type="bibr" rid="c61">61</xref></sup>.</p>
<p>Our study presents a few limitations. Although we successfully benchmarked the performance of the LFAs to a quantitative assay<sup><xref ref-type="bibr" rid="c39">39</xref></sup>, we did not determine the neutralizing potential of these antibodies. Secondly, samples were acquired when PCR testing was restricted to severely ill patients. For epidemiological studies and population surveillance, it will be important to evaluate assay performance on asymptomatic individuals.</p>
<p>In conclusion, our study provides a public resource to aid researchers, healthcare providers, public health professionals, and industries impacted by the pandemic such as airlines, in choosing the appropriate LFAs for their intended use cases.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>All evaluation data are available in a public repository: <ext-link ext-link-type="uri" xlink:href="https://covidinnovation.partners.org/evaluation/">https://covidinnovation.partners.org/evaluation/</ext-link>
Web app to generate positive predictive values is available online: <ext-link ext-link-type="uri" xlink:href="https://covid.omics.kitchen">https://covid.omics.kitchen</ext-link>.</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://covidinnovation.partners.org/evaluation/">https://covidinnovation.partners.org/evaluation/</ext-link>
</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://covid.omics.kitchen">https://covid.omics.kitchen</ext-link>
</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>This study was possible through the Diagnostics Pillar of the Mass General Brigham COVID Center for Innovation (MGBCCI) (<ext-link ext-link-type="uri" xlink:href="https://covidinnovation.partners.org/">https://covidinnovation.partners.org/</ext-link>), predominantly staffed by volunteers. The LFA horizon scan and selection was performed by the Direct-to-Consumer working group, and the Diagnostics Accelerator and Validation working group developed the protocols and performed the evaluations. The study is supported by funding from the Massachusetts Consortium on Pathogen Readiness (MassCPR) (<ext-link ext-link-type="uri" xlink:href="https://masscpr.hms.harvard.edu/">https://masscpr.hms.harvard.edu/</ext-link>).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Dong</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Du</surname>, <given-names>H.</given-names></string-name> &#x0026; <string-name><surname>Gardner</surname>, <given-names>L.</given-names></string-name> <article-title>An interactive web-based dashboard to track COVID-19 in real time</article-title>. <source>Lancet Infect Dis</source> <volume>20</volume>, <fpage>533</fpage>&#x2013;<lpage>534</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><collab>Editors. Dying in a Leadership Vacuum</collab>. <source>N Engl J Med</source> <volume>383</volume>, <fpage>1479</fpage>&#x2013;<lpage>1480</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Looi</surname>, <given-names>M.K.</given-names></string-name> <article-title>Covid-19: Is a second wave hitting Europe?</article-title> <source>BMJ</source> <volume>371</volume>, <fpage>m4113</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Wiersinga</surname>, <given-names>W.J.</given-names></string-name>, <string-name><surname>Rhodes</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Cheng</surname>, <given-names>A.C.</given-names></string-name>, <string-name><surname>Peacock</surname>, <given-names>S.J.</given-names></string-name> &#x0026; <string-name><surname>Prescott</surname>, <given-names>H.C.</given-names></string-name> <article-title>Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review</article-title>. <source>JAMA</source> <volume>324</volume>, <fpage>782</fpage>&#x2013;<lpage>793</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Oran</surname>, <given-names>D.P.</given-names></string-name> &#x0026; <string-name><surname>Topol</surname>, <given-names>E.J.</given-names></string-name> <article-title>Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review</article-title>. <source>Ann Intern Med</source> <volume>173</volume>, <fpage>362</fpage>&#x2013;<lpage>367</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="other"><string-name><surname>Havers</surname>, <given-names>F.P.</given-names></string-name> <etal>et al..</etal> <article-title>Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020</article-title>. <source>JAMA Intern Med</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Ehrlich</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Boneva</surname>, <given-names>D.</given-names></string-name> &#x0026; <string-name><surname>Elkbuli</surname>, <given-names>A.</given-names></string-name> <article-title>The intersection of viral illnesses: A seasonal influenza epidemic amidst the COVID-19 pandemic</article-title>. <source>Ann Med Surg (Lond)</source> <volume>60</volume>, <fpage>41</fpage>&#x2013;<lpage>43</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Tahmasebi</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Khosh</surname>, <given-names>E.</given-names></string-name> &#x0026; <string-name><surname>Esmaeilzadeh</surname>, <given-names>A.</given-names></string-name> <article-title>The outlook for diagnostic purposes of the 2019-novel coronavirus disease</article-title>. <source>J Cell Physiol</source> <volume>235</volume>, <fpage>9211</fpage>&#x2013;<lpage>9229</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Kumar</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Nagpal</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kaushik</surname>, <given-names>S.</given-names></string-name> &#x0026; <string-name><surname>Mendiratta</surname>, <given-names>S.</given-names></string-name> <article-title>COVID-19 diagnostic approaches: different roads to the same destination</article-title>. <source>Virusdisease</source> <volume>31</volume>, <fpage>97</fpage>&#x2013;<lpage>105</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="other"><string-name><surname>Hellou</surname>, <given-names>M.M.</given-names></string-name> <etal>et al..</etal> <article-title>Nucleic-acid-amplification tests from respiratory samples for the diagnosis of coronavirus infections: systematic review and meta-analysis</article-title>. <source>Clin Microbiol Infect</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>D&#x2019;Cruz</surname>, <given-names>R.J.</given-names></string-name>, <string-name><surname>Currier</surname>, <given-names>A.W.</given-names></string-name> &#x0026; <string-name><surname>Sampson</surname>, <given-names>V.B.</given-names></string-name> <article-title>Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)</article-title>. <source>Front Cell Dev Biol</source> <volume>8</volume>, <fpage>468</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Pecora</surname>, <given-names>N.D.</given-names></string-name> &#x0026; <string-name><surname>Zand</surname>, <given-names>M.S.</given-names></string-name> <article-title>Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning</article-title>. <source>Clin Lab Med</source> <volume>40</volume>, <fpage>603</fpage>&#x2013;<lpage>614</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Peeling</surname>, <given-names>R.W.</given-names></string-name> <etal>et al..</etal> <article-title>Serology testing in the COVID-19 pandemic response</article-title>. <source>Lancet Infect Dis</source> <volume>20</volume>, <fpage>e245</fpage>&#x2013;<lpage>e249</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>La Marca</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal> <article-title>Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays</article-title>. <source>Reprod Biomed Online</source> <volume>41</volume>, <fpage>483</fpage>&#x2013;<lpage>499</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Pickering</surname>, <given-names>S.</given-names></string-name> <etal>et al..</etal> <article-title>Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings</article-title>. <source>PLoS Pathog</source> <volume>16</volume>, <fpage>e1008817</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Whitman</surname>, <given-names>J.D.</given-names></string-name> <etal>et al..</etal> <article-title>Evaluation of SARS-CoV-2 serology assays reveals a range of test performance</article-title>. <source>Nat Biotechnol</source> <volume>38</volume>, <fpage>1174</fpage>&#x2013;<lpage>1183</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Oliver</surname>, <given-names>S.E.</given-names></string-name> <etal>et al..</etal> <article-title>The Advisory Committee on Immunization Practices&#x2019; Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020</article-title>. <source>MMWR Morb Mortal Wkly Rep</source> <volume>69</volume>, <fpage>1922</fpage>&#x2013;<lpage>1924</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Jackson</surname>, <given-names>L.A.</given-names></string-name> <etal>et al..</etal> <article-title>An mRNA Vaccine against SARS-CoV-2 - Preliminary Report</article-title>. <source>N Engl J Med</source> <volume>383</volume>, <fpage>1920</fpage>&#x2013;<lpage>1931</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="other"><string-name><surname>Anderson</surname>, <given-names>E.J.</given-names></string-name> <etal>et al..</etal> <article-title>Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults</article-title>. <source>N Engl J Med</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="other"><string-name><surname>Walsh</surname>, <given-names>E.E.</given-names></string-name> <etal>et al..</etal> <article-title>Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates</article-title>. <source>N Engl J Med</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Dagotto</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>J.</given-names></string-name> &#x0026; <string-name><surname>Barouch</surname>, <given-names>D.H.</given-names></string-name> <article-title>Approaches and Challenges in SARS-CoV-2 Vaccine Development</article-title>. <source>Cell Host Microbe</source> <volume>28</volume>, <fpage>364</fpage>&#x2013;<lpage>370</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Poland</surname>, <given-names>G.A.</given-names></string-name>, <string-name><surname>Ovsyannikova</surname>, <given-names>I.G.</given-names></string-name> &#x0026; <string-name><surname>Kennedy</surname>, <given-names>R.B.</given-names></string-name> <article-title>SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates</article-title>. <source>Lancet</source> <volume>396</volume>, <fpage>1595</fpage>&#x2013;<lpage>1606</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Zohar</surname>, <given-names>T.</given-names></string-name> <etal>et al..</etal> <article-title>Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality</article-title>. <source>Cell</source> <volume>183</volume>, <fpage>1508</fpage>&#x2013;<lpage>1519 e1512</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="other"><string-name><surname>Lucas</surname>, <given-names>C.</given-names></string-name> <etal>et al..</etal> <article-title>Kinetics of antibody responses dictate COVID-19 outcome</article-title>. <source>MedRxiv</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ai</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Loeffelholz</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Tang</surname>, <given-names>Y.W.</given-names></string-name> &#x0026; <string-name><surname>Zhang</surname>, <given-names>W.</given-names></string-name> <article-title>Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervals</article-title>. <source>Emerg Microbes Infect</source> <volume>9</volume>, <fpage>2200</fpage>&#x2013;<lpage>2211</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Caini</surname>, <given-names>S.</given-names></string-name> <etal>et al..</etal> <article-title>Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications</article-title>. <source>Euro Surveill</source> <volume>25</volume> (<year>2020</year>).</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Lisboa Bastos</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal> <article-title>Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis</article-title>. <source>BMJ</source> <volume>370</volume>, <fpage>m2516</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Moura</surname>, <given-names>D.T.H.</given-names></string-name> <etal>et al..</etal> <article-title>Diagnostic Characteristics of Serological-Based COVID-19 Testing: A Systematic Review and Meta-Analysis</article-title>. <source>Clinics (Sao Paulo)</source> <volume>75</volume>, <fpage>e2212</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="other"><string-name><surname>Gutierrez-Cobos</surname>, <given-names>A.</given-names></string-name> <etal>et al..</etal> <article-title>Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodies</article-title>. <source>Eur J Clin Microbiol Infect Dis</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="website"><collab>FDA</collab>. <source>EUA Authorized Serology Test Performance. United States Food and Drug Administration</source> <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance">https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance</ext-link> (<year>2020</year>).</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Bermingham</surname>, <given-names>W.H.</given-names></string-name>, <string-name><surname>Wilding</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Beck</surname>, <given-names>S.</given-names></string-name> &#x0026; <string-name><surname>Huissoon</surname>, <given-names>A.</given-names></string-name> <article-title>SARS-CoV-2 serology: Test, test, test, but interpret with caution!</article-title> <source>Clin Med (Lond)</source> <volume>20</volume>, <fpage>365</fpage>&#x2013;<lpage>368</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Long</surname>, <given-names>Q.X.</given-names></string-name> <etal>et al..</etal> <article-title>Antibody responses to SARS-CoV-2 in patients with COVID-19</article-title>. <source>Nat Med</source> <volume>26</volume>, <fpage>845</fpage>&#x2013;<lpage>848</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Lou</surname>, <given-names>B.</given-names></string-name> <etal>et al..</etal> <article-title>Serology characteristics of SARS-CoV-2 infection after exposure and postsymptom onset</article-title>. <source>Eur Respir J</source> <volume>56</volume> (<year>2020</year>).</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Zhao</surname>, <given-names>J.</given-names></string-name> <etal>et al..</etal> <article-title>Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019</article-title>. <source>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</source> <volume>71</volume>, <fpage>2027</fpage>&#x2013;<lpage>2034</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="other"><string-name><surname>Tenny</surname>, <given-names>S.</given-names></string-name> &#x0026; <string-name><surname>Hoffman</surname>, <given-names>M.R.</given-names></string-name> <article-title>Prevalence. StatPearls</article-title>: <source>Treasure Island (FL)</source>, <year>2020</year>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Theel</surname>, <given-names>E.S.</given-names></string-name> <etal>et al..</etal> <article-title>The Role of Antibody Testing for SARS-CoV-2: Is There One?</article-title> <source>J Clin Microbiol</source> <volume>58</volume> (<year>2020</year>).</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="other"><string-name><surname>Jorfi</surname>, <given-names>M.</given-names></string-name> <etal>et al..</etal> <article-title>Diagnostic technology for COVID-19: comparative evaluation of antigen and serology-based SARS-CoV-2 immunoassays, and contact tracing solutions for potential use as at-home products</article-title>. <source>MedRxiv</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Charlson</surname>, <given-names>M.E.</given-names></string-name>, <string-name><surname>Pompei</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Ales</surname>, <given-names>K.L.</given-names></string-name> &#x0026; <string-name><surname>MacKenzie</surname>, <given-names>C.R.</given-names></string-name> <article-title>A new method of classifying prognostic comorbidity in longitudinal studies: development and validation</article-title>. <source>J Chronic Dis</source> <volume>40</volume>, <fpage>373</fpage>&#x2013;<lpage>383</lpage> (<year>1987</year>).</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="other"><string-name><surname>Norman</surname>, <given-names>M.</given-names></string-name> <etal>et al..</etal> <article-title>Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19</article-title>. <source>Nat Biomed Eng</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Tian</surname>, <given-names>X.</given-names></string-name> <etal>et al..</etal> <article-title>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody</article-title>. <source>Emerg Microbes Infect</source> <volume>9</volume>, <fpage>382</fpage>&#x2013;<lpage>385</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Hernaez</surname>, <given-names>R.</given-names></string-name> &#x0026; <string-name><surname>Thrift</surname>, <given-names>A.P.</given-names></string-name> <article-title>High Negative Predictive Value, Low Prevalence, and Spectrum Effect: Caution in the Interpretation</article-title>. <source>Clin Gastroenterol Hepatol</source> <volume>15</volume>, <fpage>1355</fpage>&#x2013;<lpage>1358</lpage> (<year>2017</year>).</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Kissler</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Tedijanto</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Goldstein</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Grad</surname>, <given-names>Y.H.</given-names></string-name> &#x0026; <string-name><surname>Lipsitch</surname>, <given-names>M.</given-names></string-name> <article-title>Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period</article-title>. <source>Science</source> <volume>368</volume>, <fpage>860</fpage>&#x2013;<lpage>868</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Alter</surname>, <given-names>G.</given-names></string-name> &#x0026; <string-name><surname>Seder</surname>, <given-names>R.</given-names></string-name> <article-title>The Power of Antibody-Based Surveillance</article-title>. <source>N Engl J Med</source> <volume>383</volume>, <fpage>1782</fpage>&#x2013;<lpage>1784</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="other"><string-name><surname>Neagu</surname>, <given-names>M.</given-names></string-name> <article-title>The bumpy road to achieve herd immunity in COVID-19</article-title>. <source>J Immunoassay Immunochem</source>, <fpage>1</fpage>&#x2013;<lpage>18</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="other"><string-name><surname>Nilles</surname>, <given-names>E.J.</given-names></string-name> <etal>et al..</etal> <article-title>Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2</article-title>. <source>medRxiv</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Corbett</surname>, <given-names>K.S.</given-names></string-name> <etal>et al..</etal> <article-title>SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness</article-title>. <source>Nature</source> <volume>586</volume>, <fpage>567</fpage>&#x2013;<lpage>571</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Badnjevic</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Pokvic</surname>, <given-names>L.G.</given-names></string-name>, <string-name><surname>Dzemic</surname>, <given-names>Z.</given-names></string-name> &#x0026; <string-name><surname>Becic</surname>, <given-names>F.</given-names></string-name> <article-title>Risks of emergency use authorizations for medical products during outbreak situations: a COVID-19 case study</article-title>. <source>Biomed Eng Online</source> <volume>19</volume>, <fpage>75</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="other"><string-name><surname>Tan</surname>, <given-names>S.S.</given-names></string-name>, <string-name><surname>Chew</surname>, <given-names>K.L.</given-names></string-name>, <string-name><surname>Saw</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Jureen</surname>, <given-names>R.</given-names></string-name> &#x0026; <string-name><surname>Sethi</surname>, <given-names>S.</given-names></string-name> <article-title>Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results</article-title>. <source>J Clin Pathol</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Gill</surname>, <given-names>D.</given-names></string-name> &#x0026; <string-name><surname>Ponsford</surname>, <given-names>M.J.</given-names></string-name> <article-title>Testing for antibodies to SARS-CoV-2</article-title>. <source>BMJ</source> <volume>371</volume>, <fpage>m4288</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Kullar</surname>, <given-names>R.</given-names></string-name> <etal>et al..</etal> <article-title>Racial Disparity of Coronavirus Disease 2019 in African American Communities</article-title>. <source>J Infect Dis</source> <volume>222</volume>, <fpage>890</fpage>&#x2013;<lpage>893</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Long</surname>, <given-names>Q.X.</given-names></string-name> <etal>et al..</etal> <article-title>Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections</article-title>. <source>Nat Med</source> <volume>26</volume>, <fpage>1200</fpage>&#x2013;<lpage>1204</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Ibarrondo</surname>, <given-names>F.J.</given-names></string-name> <etal>et al..</etal> <article-title>Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19</article-title>. <source>N Engl J Med</source> <volume>383</volume>, <fpage>1085</fpage>&#x2013;<lpage>1087</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Kutsuna</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Asai</surname>, <given-names>Y.</given-names></string-name> &#x0026; <string-name><surname>Matsunaga</surname>, <given-names>A.</given-names></string-name> <article-title>Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19</article-title>. <source>N Engl J Med</source> <volume>383</volume>, <fpage>1695</fpage>&#x2013;<lpage>1696</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Milani</surname>, <given-names>G.P.</given-names></string-name> <etal>et al..</etal> <article-title>Serological follow-up of SARS-CoV-2 asymptomatic subjects</article-title>. <source>Sci Rep</source> <volume>10</volume>, <fpage>20048</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="other"><string-name><surname>To</surname>, <given-names>K.K.</given-names></string-name> <etal>et al..</etal> <article-title>COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing</article-title>. <source>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="other"><string-name><surname>Cohen</surname>, <given-names>J.I.</given-names></string-name> &#x0026; <string-name><surname>Burbelo</surname>, <given-names>P.D.</given-names></string-name> <article-title>Reinfection with SARS-CoV-2: Implications for Vaccines</article-title>. <source>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="other"><string-name><surname>Mulder</surname>, <given-names>M.</given-names></string-name> <etal>et al..</etal> <article-title>Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report</article-title>. <source>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</source> (<year>2020</year>).</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Hussain</surname>, <given-names>A.</given-names></string-name> <etal>et al..</etal> <article-title>Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies</article-title>. <source>Biomed Pharmacother</source> <volume>130</volume>, <fpage>110559</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="website"><collab>WHO</collab>. <source>&#x201C;Immunity passports&#x201D; in the context of COVID-19. World Health Organization commentaries</source> <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19">https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19</ext-link>. (<year>2020</year>).</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Waller</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Rubin</surname>, <given-names>G.J.</given-names></string-name>, <string-name><surname>Potts</surname>, <given-names>H.W.W.</given-names></string-name>, <string-name><surname>Mottershaw</surname>, <given-names>A.L.</given-names></string-name> &#x0026; <string-name><surname>Marteau</surname>, <given-names>T.M.</given-names></string-name> <article-title>&#x2018;Immunity Passports&#x2019; for SARS-CoV-2: an online experimental study of the impact of antibody test terminology on perceived risk and behaviour</article-title>. <source>BMJ Open</source> <volume>10</volume>, <fpage>e040448</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="other"><string-name><surname>Brown</surname>, <given-names>R.C.H.</given-names></string-name>, <string-name><surname>Kelly</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Wilkinson</surname>, <given-names>D.</given-names></string-name> &#x0026; <string-name><surname>Savulescu</surname>, <given-names>J.</given-names></string-name> <article-title>The scientific and ethical feasibility of immunity passports</article-title>. <source>Lancet Infect Dis</source> (<year>2020</year>).</mixed-citation></ref>
</ref-list>
<sec id="s5">
<title>Online Supplement</title>
<sec id="s5a">
<title>Supplementary Methods</title>
<sec id="s5a1">
<title>Analysis</title>
<p>Computational analyses were performed in R/markdown. LFA evaluation reports are available (<ext-link ext-link-type="uri" xlink:href="http://publicdata.omics.kitchen/Projects/MGBCCI/LFA/VendorReports/">http://publicdata.omics.kitchen/Projects/MGBCCI/LFA/VendorReports/</ext-link>).</p>
<p>Formulae for computing performance metrics and confidence intervals are provided below. IgG/IgM bands were called via visual inspection by two experienced human operators. Invalid LFAs (e.g. missing a control band) were excluded entirely from further analysis and the sample was not re-run.</p>
<p>A score was computed for each sample/assay/antibody combination, using the following algorithm:
<list list-type="simple">
<list-item><label>-</label><p>Each of N operators reading the LFA were assigned a weight of 1/N to final score</p></list-item>
<list-item><label>-</label><p>If an operator observed a band, the score would increase by 1/N. If the operator saw no band, the score would decrease by 1/N</p></list-item>
</list></p>
<p>This process was performed separately for the IgG and IgM channels, with an overall score produced for each antibody. This per-sample/per-antibody score thus has the following values: &#x2212;1 (all operators agree: no band), 0 (operators disagree), and &#x002B;1 (all operators agree: band observed). Given that COVID-19 remains, even in late 2020, a low-prevalence disease, we apply a conservative case definition (score &#x2265;0), where discordant operator readings (score=0) are classed as negative for presence of the antibody, in order to favor specificity. A combined IgG and IgM score was computed as the average of the two individual scores: (IgG&#x002B;IgM)/2.</p>
<p>Reproducibility analysis used the same scoring system above. Tests of the COVID&#x002B; pool that received a score &#x003E;0 were called &#x201C;correct&#x201D;. COVID-tests were ones that received a score &#x003C;0. A score of 1 or &#x2212;1 was called &#x201C;consistent&#x201D;, with all other scores indicating disagreement between operators called as &#x201C;inconsistent.&#x201D; These two classifications were concatenated to produce the outcomes &#x201C;correct consistent&#x201D;, where both operators agreed on the correct outcome, &#x201C;incorrect consistent,&#x201D; where both operators agreed on the incorrect outcome, and &#x201C;inconsistent,&#x201D; where operators disagreed on the outcome. The outcome of each individual test was plotted as a proportion of total tests of each pool on each of the two days of testing.</p>
</sec>
<sec id="s5a2">
<title>Webapp</title>
<p>We developed an interactive web-application (<ext-link ext-link-type="uri" xlink:href="https://covid.omics.kitchen">https://covid.omics.kitchen</ext-link>) to help visualize false positive and false negative LFA readings based on test accuracy and disease prevalence. We incorporate data from the 20 LFAs reported here as well as the 6 LFAs evaluated by Whitman, et al<sup><xref ref-type="bibr" rid="c16">16</xref></sup>. County, State, and US-wide disease rates (cumulative numbers of individuals confirmed to have been infected since the start of the outbreak) are pulled dynamically from the New York Times github repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/nytimes/covid-19-data">https://github.com/nytimes/covid-19-data</ext-link>). The webapp is implemented in d3.js JavaScript and hosted on Amazon Web Services AWS/Amplify.</p>
</sec>
<sec id="s5a3">
<title>Formula</title>
<sec id="s5a3a">
<title>Sensitivity</title>
<list list-type="bullet">
<list-item><p><italic>n</italic> = <italic>TP</italic> &#x002B; <italic>FN</italic></p></list-item>
<list-item><p><inline-formula><alternatives><inline-graphic xlink:href="20248998v1_inline1.gif"/></alternatives></inline-formula></p></list-item>
<list-item><p><inline-formula><alternatives><inline-graphic xlink:href="20248998v1_inline2.gif"/></alternatives></inline-formula></p></list-item>
<list-item><p><inline-formula><alternatives><inline-graphic xlink:href="20248998v1_inline3.gif"/></alternatives></inline-formula></p></list-item>
</list>
</sec>
<sec id="s5a3b">
<title>Specificity</title>
<list list-type="bullet">
<list-item><p><italic>n = TN</italic> &#x002B; <italic>FP</italic></p></list-item>
<list-item><p><inline-formula><alternatives><inline-graphic xlink:href="20248998v1_inline4.gif"/></alternatives></inline-formula></p></list-item>
<list-item><p><inline-formula><alternatives><inline-graphic xlink:href="20248998v1_inline5.gif"/></alternatives></inline-formula></p></list-item>
<list-item><p><inline-formula><alternatives><inline-graphic xlink:href="20248998v1_inline6.gif"/></alternatives></inline-formula></p></list-item>
</list>
</sec>
<sec id="s5a3c">
<title>PPV</title>
<list list-type="bullet">
<list-item><p><italic>n = TP</italic> &#x002B; <italic>FP</italic></p></list-item>
<list-item><p><inline-formula><alternatives><inline-graphic xlink:href="20248998v1_inline7.gif"/></alternatives></inline-formula></p></list-item>
<list-item><p><inline-formula><alternatives><inline-graphic xlink:href="20248998v1_inline8.gif"/></alternatives></inline-formula></p></list-item>
<list-item><p><inline-formula><alternatives><inline-graphic xlink:href="20248998v1_inline9.gif"/></alternatives></inline-formula></p></list-item>
</list>
</sec>
<sec id="s5a3d">
<title>NPV</title>
<list list-type="bullet">
<list-item><p><italic>n = TN</italic> &#x002B; <italic>FN</italic></p></list-item>
<list-item><p><inline-formula><alternatives><inline-graphic xlink:href="20248998v1_inline10.gif"/></alternatives></inline-formula></p></list-item>
<list-item><p><inline-formula><alternatives><inline-graphic xlink:href="20248998v1_inline11.gif"/></alternatives></inline-formula></p></list-item>
<list-item><p><inline-formula><alternatives><inline-graphic xlink:href="20248998v1_inline12.gif"/></alternatives></inline-formula></p></list-item>
</list>
<table-wrap id="tblS1" orientation="portrait" position="float">
<label>Supplementary Table 1:</label>
<caption><p>LFA commercial kit information, sample requirements, and protocol details</p></caption>
<graphic xlink:href="20248998v1_tblS1.tif"/>
</table-wrap>
<table-wrap id="tblS2" orientation="portrait" position="float">
<label>Supplementary Table 2:</label>
<caption><p>IFU clarity rubric. Kits were assigned one point for each criteria listed if met</p></caption>
<graphic xlink:href="20248998v1_tblS2.tif"/>
</table-wrap>
<table-wrap id="tblS3" orientation="portrait" position="float">
<label>Supplementary Table 3.</label>
<caption><p>Usability ratings and description of kit components.</p></caption>
<graphic xlink:href="20248998v1_tblS3.tif"/>
</table-wrap>
<table-wrap id="tblS4" orientation="portrait" position="float">
<label>Supplementary Table 4.</label>
<caption><p>LFA Limits of detection estimated from anti-spike antibodies concentrations measured by Simoa; amounts reflect lowest antibody concentrations in plasma samples that show a positive band</p></caption>
<graphic xlink:href="20248998v1_tblS4.tif"/>
</table-wrap>
</sec>
</sec>
</sec>
</sec>
</back>
</article>